Crucell boosted by gene delivery deal
Crucell signs a new agreement for its PER.C6 biological drug
production technology with GeneMax, a US firm developing vaccines
Degussa sees sales, profits slump in second quarter
Degussa follows its peers in the speciality chemicals industry by
posting weak interim results held back by currency factors, raw
material costs and lower demand.
Novartis may shut Indian rifampicin plant
Swiss pharmaceuticals giant Novartis is planning to shut its only
manufacturing facility in India, at Mahad in Maharashtra, because
of increasing competition.
China Pharma triples net profit
China Pharma sees revenues and net profits soar in first half, but
analysts say bulk drugs may come under pricing pressure going
Genetix makes first sale of cell picker
The UK's Genetix, which makes gene and protein research equipment,
said it had received orders from leading pharmaceutical groups for
two of its new products.
Swedish biotechs link up
Pyrosequencing, a genetic analysis systems manufacturer, has
acquired a 94.1 per cent stake in chemical synthesis concern
Personal Chemistry in an all-stock transaction.
USA speeds generic approvals
The pharmaceutical industry is facing the possibility of earlier
generic competition for its branded products from 18 August, when
new legislation in the USA comes into effect.
Japan follows suit on PPA ban
Japan's Ministry of Health, Labour and Welfare has ordered
companies to stop producing over-the-counter (OTC) pharmaceuticals
containing phenylpropanolamine (PPA), linked to an increased risk
of haemorrhagic stroke.
GSK licenses bioavailability patent
A patent covering a technology aimed at improving the oral
bioavailability of cancer drugs has been licensed by
EuropaBio names keynote speakers
The organisers of CORDIA EuropaBio 2003 have revealed the keynote
speakers for the 'largest convention in Europe for trade,
investment, partnership and information exchange'.
FTC takes on alleged process control software monopoly
The US FTC has taken issue with the merger between Aspen Technology
and Hyprotech in 2002, alleging that it gave the combined firm a
too-dominant position in process control software.
BASF sees no recovery until fourth quarter
BASF, the world's largest chemicals company, has said that it will
expand an ongoing restructuring program in North America after
reporting lower-than-expected second-quarter sales and profits.
Caliper sheds jobs after Zymark buy
Caliper has cut 9 per cent of its staff as part of a restructuring
exercise following its $72 million acquisition of lab automation
Bayer sales on the slide in second quarter
Bayer has reported a decline in net profits for the second quarter
of 2003, with analysts expressing concerns that litigations costs
could hold back full-year earnings.
Cambrex sells non-core business
Cambrex plans to sell off its Rutherford Chemicals business for $64
million (€56m) to allow it to focus on its human health and